市場調查報告書
商品編碼
1554352
2024-2032 年日本寡核苷酸合成市場報告(按產品、應用(PCR 引子、PCR 測定和麵板、定序、DNA 微陣列、螢光原位雜合技術、反義寡核苷酸等)、最終用途和區域)Japan Oligonucleotide Synthesis Market Report by Product, Application (PCR Primers, PCR Assays and Panels, Sequencing, DNA Microarrays, Fluorescence In-Situ Hybridization, Antisense Oligonucleotides, and Others), End Use, and Region 2024-2032 |
日本寡核苷酸合成市場規模預計在 2024 年至 2032 年期間將呈現 11.70% 的成長率 (CAGR)。新型治療策略的廣泛採用,加上生物資訊學和資料科學的顯著成長,主要推動了市場的成長。
寡核苷酸合成是建構具有特定序列的短 DNA 或 RNA 分子(稱為寡核苷酸)的過程。這些序列的長度可以從幾個鹼基到大約 200 個核苷酸不等。該過程通常在受控實驗室環境中透過化學合成進行,通常利用固相亞磷醯胺化學。在這種方法中,核苷酸被順序添加到不斷成長的鏈中,每次添加都涉及一系列化學反應。這項技術使科學家能夠為一系列應用創建客製化的寡核苷酸,包括基因合成、聚合酶鍊式反應 (PCR)、CRISPR-Cas9 等基因編輯工具和分子診斷測試。寡核苷酸合成的進步極大地加速了基因組學和分子生物學的研究,在醫學和生物學研究的眾多突破中發揮了關鍵作用。
日本寡核苷酸市場的主要動力是人口中遺傳疾病發生率的增加。這就需要探索新的治療方法,其中基於寡核苷酸的療法發揮重要作用。例如,利用小干擾 RNA (siRNA) 和反義寡核苷酸的療法正在研究並應用於治療杜氏肌肉營養不良症和脊髓性肌肉萎縮症等遺傳性疾病。因此,遺傳疾病的日益普及不僅在日本而且在更廣泛的範圍內推動了需求。此外,生物資訊學和資料科學的擴展直接影響寡核苷酸合成領域。分析廣泛基因組資料集的能力不斷增強,對創新寡核苷酸的合成產生了更大的需求,從而對市場產生了積極影響。此外,寡核苷酸,特別是反義寡核苷酸,已被證明在表觀遺傳學研究和治療中有效,促進基因表現調節並有助於良好的市場前景。此外,製藥公司、生技公司和研究機構之間的合作和夥伴關係已成為推動遺傳疾病寡核苷酸療法的開發和商業化的關鍵驅動力。這些合作預計將在預測期內推動區域市場的發展。
IMARC Group提供了每個細分市場的主要趨勢的分析,以及 2024-2032 年國家層級的預測。我們的報告根據產品、應用和最終用途對市場進行了分類。
該報告根據產品提供了詳細的市場細分和分析。這包括合成的寡核苷酸產品、試劑、設備和服務。
報告還提供了基於應用程式的詳細市場細分和分析。這包括 PCR 引子、PCR 檢測和組合、定序、DNA 微陣列、螢光原位雜合技術 (FISH)、反義寡核苷酸等。
該報告根據最終用途提供了詳細的市場細分和分析。這包括製藥和生物技術公司、醫院和診斷實驗室以及學術研究機構。
該報告還對所有主要區域市場進行了全面分析,包括關東地區、關西/近畿地區、中部/中部地區、九州沖繩地區、東北地區、中國地區、北海道地區和四國地區。
市場研究報告也對競爭格局進行了全面分析。報告涵蓋了市場結構、關鍵參與者定位、最佳制勝策略、競爭儀表板和公司評估象限等競爭分析。此外,也提供了所有主要公司的詳細資料。
此處未提供公司名稱,因為這是目錄範例。報告中提供了完整的清單。
Japan oligonucleotide synthesis market size is projected to exhibit a growth rate (CAGR) of 11.70% during 2024-2032. The widespread adoption of novel therapeutic strategies, coupled with significant growth of bioinformatics and data science, is primarily driving the market growth.
Oligonucleotide synthesis is the procedure for constructing short DNA or RNA molecules, known as oligonucleotides, with a specific sequence. These sequences can vary in length from just a few bases to approximately 200 nucleotides. This process is typically carried out through chemical synthesis in a controlled laboratory setting, often utilizing solid-phase phosphoramidite chemistry. In this approach, nucleotides are sequentially added to a growing chain, with each addition involving a series of chemical reactions. This technology allows scientists to create tailor-made oligonucleotides for a range of applications, including gene synthesis, polymerase chain reaction (PCR), gene editing tools like CRISPR-Cas9, and molecular diagnostic tests. Advances in oligonucleotide synthesis have greatly accelerated research in genomics and molecular biology, playing a pivotal role in numerous breakthroughs in medical and biological research.
The Japanese market for oligonucleotides is primarily propelled by the increasing incidence of genetic diseases within the population. This necessitates the exploration of novel therapeutic approaches, with a significant role being played by oligonucleotide-based therapies. For example, therapies utilizing small interfering RNAs (siRNAs) and antisense oligonucleotides are being researched and applied in the treatment of genetic disorders like Duchenne muscular dystrophy and spinal muscular atrophy. Consequently, the growing prevalence of genetic diseases is driving demand not only in Japan but also on a wide scale. Furthermore, the expansion of bioinformatics and data science is directly impacting the oligonucleotide synthesis sector. The increasing capacity to analyze extensive genomic datasets is positively influencing the market by generating greater demand for the synthesis of innovative oligonucleotides. Additionally, oligonucleotides, particularly antisense oligonucleotides, have proven effective in epigenetic research and therapy, facilitating gene expression modulation and contributing to a favorable market outlook. Moreover, collaborations and partnerships between pharmaceutical companies, biotechnology firms, and research institutions have become crucial drivers in advancing the development and commercialization of oligonucleotide therapies for genetic diseases. These collaborative efforts are expected to fuel the regional market over the forecasted period.
IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the country level for 2024-2032. Our report has categorized the market based on product, application, and end use.
The report has provided a detailed breakup and analysis of the market based on the product. This includes synthesized oligonucleotide products, reagents, equipment, and services.
A detailed breakup and analysis of the market based on the application have also been provided in the report. This includes PCR primers, PCR assays and panels, sequencing, DNA microarrays, fluorescence in-situ hybridization (FISH), antisense oligonucleotides, and others.
The report has provided a detailed breakup and analysis of the market based on the end use. This includes pharmaceutical and biotechnology companies, hospital and diagnostic laboratories, and academic research institutes.
The report has also provided a comprehensive analysis of all the major regional markets, which include Kanto Region, Kansai/Kinki Region, Central/ Chubu Region, Kyushu-Okinawa Region, Tohoku Region, Chugoku Region, Hokkaido Region, and Shikoku Region.
The market research report has also provided a comprehensive analysis of the competitive landscape. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.
Company names have not been provided here as this is a sample TOC. The complete list is provided in the report.